Reality Bites again for Amgen
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
ALX has a Chinese challenger
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Roche reins in the TIGIT expectations
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
